



Dec 2025

Company profile

TSEC 1733

Industry IVD Medical Device

Operation Locations

.Head quarter: No. 7, Li-Hsin 5th Rd., Hsinchu Science Park, Hsinchu, Taiwan

.Tao Yuan Factory: No. 180, Lane 70, Wuqing Rd., Dayuan Dist., Taoyuan City, Taiwan

.Suzhou Corp.: Room 106, No.2, Kecheng Road, SIP, Suzhou, China

.Omnis Health LLC : 1736 River Hills Dr Suite 6, Nashville, TN 37210,USA

Started 12/02/1997

IPO 09/17/2001(1733 TSEC)

Capital NTD 1 Billion

Chairman/CEO Thomas Shen PhD

Employees 660 people (upto 9/30/2025)

Milestone

1997-2001

1997 ApexBio set-up
1998 BGM FDA 510K approval
2001 Transit IPO listed to TSEC
2001 1st time FDA on-site inspection
w/o 483

2002-2006

2002 ISO9001/13485 Notified
2003 CE IVDD notified
2004 Taiwan GMP notified
2006 2nd time FDA on-site inspection
w/o 483

2007-2011

2009 Taoyuan factory set-up
2011 AEO certified by Customs Admin
2011 3rd time FDA on-site inspection
w/o 483

2012-2016

2012 ApexBio Suzhou Corp se-up
2013 1st Taiwan MITTELSTAND
Award from MOEA
2015 ISO14001/OHSAS18001 notified
2016 4th time FDA on-site inspection
w/o 483

2017-2021

2017 Acquired Omnis Health LLC
2019 ISO45001:2018 notified

2022-2025

2023 MDSAP(USA/Canada/Brazil) notified
2024 MDSAP(Japan/Australia) notified
2024 Flu rapid test TFDA QMS notified
2025 MCS Eclipse PLUS 2025 Taiwan
Excellence Award
2025 SA8000 notified

Quality System

Region	The Authority	Regulatory compliance
Taiwan	TFDA	QMS
EU	CE	ISO 13485:2016 CE mark number:CE0197 EN ISO 15197:2015
USA	FDA	Quality System Regulation (21 CFR Part 820) 510K's on-site audit w/o 483 citations 2023 MDSAP (USA/Canada/Brazil)
China	NMPA	Medical Device Class II
Brazil	ANVISA	2017 passed on-site audit 2023 MDSAP (USA/Canada/Brazil)
Canada	Health Canada	2023 MDSAP (USA/Canada/Brazil)
Japan	PMDA	2024 MDSAP (Japan/Australia)
Australia	TGA	2024 MDSAP (Japan/Australia)

Product Series



DIABETES CARE



HOME DIAGNOSTICS



CLINICAL & LABORATORY



POINT-OF-CARE

Home diagnostics products



New pipeline product

■ Rapid test

TFDA QMS passed

- COVID-19 Antigen Rapid Test Kit
- KP Rapid Test Kit
- Influenza Rapid Test Kit

Developing items:

- Vector-borne Disease Detection for Mosquito-borne Illnesses
- Economic Animal and Animal Epidemic Prevention Detection
- DOA


■ Home use CGM



Technology Innovation in Lateral Flow Rapid Tests

Public health, epidemic prevention & surveillance,
and professional diagnosis by medical institutions

Development Initiatives



Global sales distribution


Territory	2023	2024	2025/1-3Q
America	41%	39%	48%
EU	44%	48%	43%
Asia	13.5%	12%	8%
Africa	1.5%	1%	1%

Finance Performance


	2023	2024	2025/1-3Q
Revenue	1,676,537	1,852,211	1,505,913
Gross margin	531,116	521,342	406,378
Operation profit	141,716	128,464	107,485
Profit after tax	115,714	128,104	112,837
EPS	1.16	1.28	1.13
G/M ratio	31%	28%	27%
Shipped Meter Qty (kit)	1,189K	1,368K	953K
Shipped Strip Qty (pcs)	900M	859M	715M

Product ratio

2024



2025/1-3Q



Non-BGM

Hemoglobin/Ketone/Uric Acid/Lactate/Cholesterol/
Pesticide quick check etc.

the 11th Corporate Governance Evaluation (2024)

Category	Total number of indicators		Distribution weight		Points for satisfied indicators		Number of inapplicable indicators		AA/A+ Extra Credit Indicators	
	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024
Protecting Shareholder Rights and Interests and Treating Shareholders Equitably	18	14	0.22	0.19	15	13	0	0	1	1
Enhancing Board Composition and Operation	25	22	0.31	0.29	19	17	0	0	3	3
Increasing Information Transparency	15	13	0.19	0.17	10	10	0	0	1	1
Putting Corporate Social Responsibility into Practice	22	26	0.28	0.35	14	21	0	0	1	2
Others	2	0	-	-	-	-	-	-	-	-

Total score: **88.4**

Ranking (SEC): **21%~35%**

Industry Category: Market Capitalization Under NT\$5 Billion, ranking : **2% %~10%**

Thank you

